Advances in Molecular OncologyAdvances in Molecular OncologyУспехи молекулярной онкологии2313-805X2413-3787Publishing House ABV Press79510.17650/2313-805X-2026-13-2-49-61REVIEW ARTICLESОБЗОРНЫЕ СТАТЬИReview ArticleCancer stem cells as a possible cause of castration-resistant prostate cancerОпухолевые стволовые клетки как вероятная причина развития кастрат-резистентного рака предстательной железыhttps://orcid.org/0009-0003-7673-1766ShayakhmetovRustam I.ШаяхметовРустам Ильгизович
Russian Federation

Institute of Urology and Clinical Oncology

Институт урологии и клинической онкологии

sheikhakhmetov@yandex.ruhttps://orcid.org/0009-0007-7467-5034LeT. Ch.ЛеТ. Ч.
Russian Federation

Institute of Urology and Clinical Oncology

Институт урологии и клинической онкологии

sheikhakhmetov@yandex.ruhttps://orcid.org/0000-0001-9393-2875IshmetovaD. V.ИшметоваД. В.
Russian Federation

Institute of Urology and Clinical Oncology

Институт урологии и клинической онкологии

sheikhakhmetov@yandex.ruhttps://orcid.org/0009-0009-8191-9951RakhmatullinaA. I.РахматуллинаА. И.
Russian Federation

Institute of Urology and Clinical Oncology

Институт урологии и клинической онкологии

sheikhakhmetov@yandex.ruIshmugulovR. R.ИшемгуловР. Р.
Russian Federation

Institute of Urology and Clinical Oncology

Институт урологии и клинической онкологии

prorectornir@bashgmu.ruhttps://orcid.org/0000-0003-2125-4897PavlovV. N.ПавловВ. Н.
Russian Federation

Institute of Urology and Clinical Oncology

Институт урологии и клинической онкологии

sheikhakhmetov@yandex.ruBashkir State Medical University, Ministry of Health of RussiaФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава России19062026132496117072025Copyright ©; 2026, ABV-PressCopyright ©; 2026, АБВ-пресс2026ABV-PressАБВ-прессhttps://creativecommons.org/licenses/by/4.0/https://umo.abvpress.ru/jour/article/view/795

In recent years, the study of cancer stem cells and their role in the development of resistance to antitumor therapy, the progression and recurrence of malignant neoplasms has become an important topic of research. Many experimental studies have shown that cancer stem cells may be responsible for the initiation and progression of prostate cancer. The development of castration-resistant prostate cancer is accompanied by changes in the activity of many signaling pathways, such as WNT/β-catenin, interleukin 6 /STAT3, ALDH1, Notch1 and Hedgehog which regulate the genes responsible for pluripotency, self-renewal, and differentiation, indicating the presence of stem-like cells in the tumor.

В последние годы актуально изучение опухолевых стволовых клеток и их роли в развитии резистентности к противоопухолевой терапии, прогрессии и рецидивировании злокачественных новообразований. Результаты многих экспериментальных исследований показывают, что эти клетки могут быть ответственны за инициацию и прогрессирование рака предстательной железы. Развитие кастрат-резистентного рака предстательной железы сопровождается изменениями активности многих сигнальных путей, таких как WNT/β-катенин, интерлейкин 6/STAT3, ALDH1, Notch1 и Hedgehog, которые регулируют работу генов, ответственных за плюрипотентность, самообновление и дифференцировку, что указывает на присутствие в опухоли клеток со стволовыми свойствами.

cancer stem cellsignaling pathwaycastrate-resistant prostate cancerопухолевая стволовая клеткасигнальный путькастрат-резистентный рак предстательной железыThe work was carried out with the support of the Strategic Academic Leadership Program of the Bashkir State Medical University, Ministry of Health of the Russia “Priority-2030”.Работа выполнена при поддержке Программы стратегического академического лидерства ФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава России «Приоритет-2030».Malignant neoplasms in Russia in 2017 (morbidity and mortality). Ed. by A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2019. 250 p. (In Russ.).Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петрова. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019. 250 с.Bray F., Laversanne M., Sung H. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74(3):229–63. DOI: 10.3322/caac.21834Yu C., Yao Z., Jiang Y., Keller E.T. Prostate cancer stem cell biology. Minerva Urol Nefrol 2012;64(1):19–33.Omelchuk E.P., Kutilin D.S., Dimitriadis S.N. et al. Molecular and genetic aspects of prostate cancer radioresistance. Bulletin of Siberian Medicine 2021;20(3):182–92. (In Russ.).Омельчук Е.П., Кутилин Д.С., Димитриади С.Н. и др. Молекулярно-генетические аспекты радиорезистентности рака предстательной железы. Бюллетень сибирской медицины 2021;20(3):182–92.Virchow R. Editoral Archiv fuer pathologische Anatomie und Physiologie und fuer klinische Medizin. Berlin, 1855. (In German). Available at: https://books.google.ru/books/about/Archiv_f%C3%BCr_pathologische_Anatomie_und_P.html?id=6IYvAAAAIAAJ&redir_esc=yCohnheim J. Ueber entzundung und eiterung. Path Anat Physiol Klin Med 1867;40:1–79. Available at: https://link.springer.com/article/10.1007/BF02968135Bruce W.R., van der Gaag H. A quantitative assay for the number of murine lymphoma cells capable of proliferation in vivo. Nature 1963;199:79–80. DOI: 10.1038/199079a0Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3(7):730–7. DOI: 10.1038/nm0797-730Al-Hajj M., Wicha M.S., Benito-Hernandez A. et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100(7):3983–8. DOI: 10.1073/pnas.0530291100Kim C.F., Jackson E.L., Woolfenden A.E. et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005;121:823–35. DOI: 10.1016/j.cell.2005.03.032O’Brien C.A., Pollett A., Gallinger S., Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445(7123):106–10. DOI: 10.1038/nature05372Szotek P.P., Pieretti-Vanmarcke R., Masiakos P.T. et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci USA 2006;103(30):11154–9. DOI: 10.1073/pnas.0603672103Piccirillo S.G.M., Reynolds B.A., Zanetti N. et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006;444(7120):761–5. DOI: 10.1038/nature05349Collins A.T., Berry P.A., Hyde C. et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65(23):10946–51. DOI: 10.1158/0008-5472.CAN-05-2018Miller S.J., Lavker R.M., Sun T.T. Interpreting epithelial cancer biology in the context of stem cells: tumor properties and therapeutic implications. Biochim Biophys Acta 2005;1756(1):25–52. DOI: 10.1016/j.bbcan.2005.07.003Vezzoni L., Parmiani G. Limitations of the cancer stem cell theory. Cytotechnology 2008;58:3–9. DOI: 10.1007/s10616-008-9166-8Fabian A., Vereb G., Szollosi J. The hitchhikers guide to cancer stem cell theory: markers, pathways and therapy. Cytometry A 2013; 83(1):62–71. DOI: 10.1002/cyto.a.22206Ni C., Huang J. Dynamic regulation of cancer stem cells and clinical challenges. Clin Transl Oncol 2013;15(4):253–8. DOI: 10.1007/s12094-012-0927-7Saunders N.A., Simpson F., Thompson E.W. et al. Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. EMBO Mol Med 2012;4(8):675–84. DOI: 10.1002/emmm.201101131Di Lorenzo G., Autorino R., D’Armiento F.P. et al. Expression of proto-oncogene c-kit in high risk prostate cancer. Eur J Surg Oncol 2004;30(9):987–92. DOI: 10.1016/j.ejso.2004.07.017Patrawala L., Calhoun-Davis T., Schneider-Broussard R. et al. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells. Cancer Res 2007;67(14):6796–805. DOI: 10.1158/0008-5472.CAN-07-0490Burger P.E., Gupta R., Xiong X. et al. High aldehyde dehydrogenase activity: a novel functional marker of murine prostate stem/progenitor cells. Stem Cells 2009;27(9):2220–8. DOI: 10.1002/stem.135Ugolkov A.V., Eisengart L.J., Luan C. et al. Expression analysis of putative stem cell markers in human benign and malignant prostate. Prostate 2011;71(1):18–25. DOI: 10.1002/pros.21217Trerotola M., Li J., Alberti S. et al. Trop-2 inhibits prostate cancer cell adhesion to fibronectin through the β1 integrin-RACK1 axis. J Cell Physiol 2012;227(11):3670–7. DOI: 10.1002/jcp.24074Fang Y., Fliss A.E., Robins D.M. et al. Hsp90 regulates androgen receptor hormone binding affinity in vivo. J Biol Chem 1996;271(45):28697–702. DOI: 10.1074/jbc.271.45.28697Askew E.B., Gampe R.T. Jr., Stanley T.B. et al. Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone. J Biol Chem 2007;282(35):25801–16. DOI: 10.1074/jbc.M703268200Balk S., Knudsen K. AR, the cell cycle, and prostate cancer. Nucl Recept Signal 2008;6:e001. DOI: 10.1621/nrs.06001Penning T.M. Dehydroepiandrosterone (DHEA)-SO4 depot and castration-resistant prostate cancer. Vitam Horm 2018;108:309–31. DOI: 10.1016/bs.vh.2018.01.007Nyquist M.D., Corella A., Coleman I. et al. Combined TP53 and RB1 Loss promotes prostate cancer resistance to a spectrum of therapeutics and confers vulnerability to replication stress. Cell Rep 2020;31(8):107669. DOI: 10.1016/j.celrep.2020.107669Van der Steen T., Tindall D.J., Huang H. Posttranslational modification of the androgen receptor in prostate cancer. Int J Mol Sci 2013;14(7):14833–59. DOI: 10.3390/ijms140714833Le T.K., Duong Q.H., Baylot V. et al. Castration-resistant prostate cancer: from uncovered resistance mechanisms to current treatments. Cancers (Basel) 2023;15(20):5047. DOI: 10.3390/cancers15205047Fu X., Liu J., Yan X. et al. Heat shock protein 70 and 90 family in prostate cancer. Life (Basel) 2022;12(10):1489. DOI: 10.3390/life12101489Truica C.I., Byers S., Gelmann E.P. Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 2000;60(17):4709–13.Wan X., Liu J., Lu J.F. et al. Activation of β-catenin signaling in androgen receptor-negative prostate cancer cells. Clin Cancer Res 2012;18(3):726–36. DOI: 10.1158/1078-0432.CCR-11-2521Rajan P., Sudbery I.M., Villasevil M.E. et al. Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy. Eur Urol 2014 ;66(1):32–9. DOI: 10.1016/j.eururo.2013.08.011Koushyar S., Meniel V.S., Phesse T.J. et al. Exploring the Wnt pathway as a therapeutic target for prostate cancer. Biomolecules 2022;12(2):309. DOI: 10.3390/biom12020309Chesire D.R., Ewing C.M., Gage W.R. et al. In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis. Oncogene 2002;21(12):2679–94. DOI: 10.1038/sj.onc.1205352Lee G.T., Kwon S.J., Kim J. et al. WNT5A induces castration-resistant prostate cancer via CCL2 and tumour-infiltrating macrophages. Br J Cancer 2018;118(5):670–8. DOI: 10.1038/bjc.2017.451Bisson I., Prowse D.M. WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res 2009;19:683–97. DOI: 10.1038/cr.2009.43Huang B., Lang X., Li X. The role of IL-6/JAK2/STAT3 signaling pathway in cancers. Front Oncol 2022;12:1023177. DOI: 10.3389/fonc.2022.1023177Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009;9(11):798–809. DOI: 10.1038/nrc2734Bronte-Tinkew D.M., Terebiznik M., Franco A. et al. Helicobacter pylori cytotoxin-associated gene A activates the signal transducer and activator of transcription 3 pathway in vitro and in vivo. Cancer Res 2009;69(2):632–9. DOI: 10.1158/0008-5472.CAN-08-1191Wu S., Rhee K.J., Albesiano E. et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nature Med 2009;15(9):1016–22. DOI: 10.1038/nm.2015Samavati L., Rastogi R., Du W. et al. STAT3 tyrosine phosphorylation is critical for interleukin 1β and interleukin-6 production in response to lipopolysaccharide and live bacteria. Mol Immunol 2009;46(8–9): 1867–77. DOI: 10.1016/j.molimm.2009.02.018Darnell J.E. Jr., Kerr I.M., Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264(5164):1415–21. DOI: 10.1126/science.8197455Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6(4):295–307. DOI: 10.1038/nri1806Wu X., Tao P., Zhou Q. et al. IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2/STAT3 signaling pathway. Oncotarget 2017;8(13):20741–50. DOI: 10.18632/oncotarget.15119Banerjee K., Resat H. Constitutive activation of STAT3 in breast cancer cells: a review. Int J Cancer 2016;138(11):2570–8. DOI: 10.1002/ijc.29923Singh A.K., Bhadauria A.S., Kumar U. et al. Novel fused oxazepino-indoles (FOIs) attenuate liver carcinogenesis via IL-6/JAK2/STAT3 signaling blockade as evidenced through data-based mathematical modeling. Life Sci 2018;201:161–72. DOI: 10.1016/j.lfs.2018.02.029Zhang X., Hu F., Li G. et al. Human colorectal cancer-derived mesenchymal stem cells promote colorectal cancer progression through IL-6/JAK2/STAT3 signaling. Cell Death Dis 2018;9(2):25. DOI: 10.1038/s41419-017-0176-3Fang X., Hong Y., Dai L. et al. CRH promotes human colon cancer cell proliferation via IL-6/JAK2/STAT3 signaling pathway and VEGF-induced tumor angiogenesis. Mol Carcinogene 2017;56(11):2434–45. DOI: 10.1002/mc.22691Wang L., Zhang F., Cui J.Y. et al. CAFs enhance paclitaxel resistance by inducing EMT through the IL-6/JAK2/STAT3 pathway. Oncol Rep 2018;39(5):2081–90. DOI: 10.3892/or.2018.6311Sun C., Yang J., Cheng H.B. et al. 2-Hydroxy-3-methylanthraquinone inhibits lung carcinoma cells through modulation of IL-6-induced JAK2/STAT3 pathway. Phytomedicine 2019;61:152848. DOI: 10.1016/j.phymed.2019.152848Zhang X., Lu H., Hong W. et al. Tyrphostin B42 attenuates trichostatin a-mediated resistance in pancreatic cancer cells by antagonizing IL-6/JAK2/STAT3 signaling. Oncol Rep 2018;39(4):1892–900. DOI: 10.3892/or.2018.6241Culig Z., Puhr M. Interleukin-6: a multifunctional targetable cytokine in human prostate cancer. Mol Cell Endocrinol 2012;360(1–2):52–8. DOI: 10.1016/j.mce.2011.05.033Adler H.L., McCurdy M.A., Kattan M.W. et al. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 1999;161(1):182–7.Schroeder A., Herrmann A., Cherryholmes G. et al. Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling. Cancer Res 2014;74(4):1227–37. DOI: 10.1158/0008-5472.CAN-13-0594Schnier J.B., Kaur G., Kaiser A. et al. Identification of cytosolic aldehyde dehydrogenase 1 from non-small cell lung carcinomas as a flavopiridol-binding protein. FEBS Lett 1999;454(1–2):100–4. DOI: 10.1016/s0014-5793(99)00773-5Li T., Su Y., Mei Y. et al. ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients’ outcome. Lab Invest 2010;90(2):234–44. DOI: 10.1038/labinvest.2009.127Kalantari E., Saadi F.H., Asgari M. et al. Increased expression of ALDH1A1 in prostate cancer is correlated with tumor aggressiveness: a tissue microarray study of iranian patients. Appl Immunohistochem Mol Morphol 2017;25(8):592–8. DOI: 10.1097/PAI.0000000000000343Matsika A., Srinivasan B., Day C. et al. Cancer stem cell markers in prostate cancer: an immunohistochemical study of ALDH1, SOX2 and EZH2. Pathology 2015;47(7):622–8. DOI: 10.1097/PAT.0000000000000325Van den Hoogen C., van der Horst G., Cheung H. et al. High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res 2010;70(12):5163–73. DOI: 10.1158/0008-5472.CAN-09-3806Shen M.M., Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 2010;24(18):1967–2000. DOI: 10.1101/gad.1965810Zhu H., Zhou X., Redfield S. et al. Elevated EXpression of Notch1 Is associated with metastasis of human malignancies. Int J Surg Pathol 2013;21(5):449–54. DOI: 10.1177/1066896913496146Stoyanova T., Riedinger M., Lin S. et al. Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer. Proc Natl Acad Sci USA 2016;113(42):E6457–66. DOI: 10.1073/pnas.1614529113Wu K., Wu M., Yang H. et al. Hypoxia promotes conversion to a stem cell phenotype in prostate cancer cells by activating HIF-1α/Notch1 signaling pathway. Clin Transl Oncol 2023;25(7):2138–52. DOI: 10.1007/s12094-023-03093-wShi F., Sun M.H., Zhou Z. et al. Tumor-associated macrophages in direct contact with prostate cancer cells promote malignant proliferation and metastasis through NOTCH1 pathway. Int J Biol Sci 2022;18(16):5994–6007. DOI: 10.7150/ijbs.73141Jiang J. Hedgehog signaling mechanism and role in cancer. Semin Cancer Biol 2022;85:107–22. DOI: 10.1016/j.semcancer.2021.04.003Cohen M.M. Jr. The hedgehog signaling network. Am J Med Genet A 2003;123A(1):5–28. DOI: 10.1002/ajmg.a.20495Lv L., Yang Z., Ma T. et al. Gli1, a potential cancer stem cell marker, is strongly associated with prognosis in prostate cancer. Int J Clin Exp Pathol 2018;11(10):4957–66.Kim T.J., Lee J.Y., Hwang T.K. et al. Hedgehog signaling protein expression and its association with prognostic parameters in prostate cancer: a retrospective study from the view point of new 2010 anatomic stage/prognostic groups. J Surg Oncol 2011;104(5):472–9. DOI: 10.1002/jso.21988Bernard D., Pourtier-Manzanedo A., Gil J. et al. Myc confers androgen-independent prostate cancer cell growth. J Clin Invest 2003;112(11):1724–31. DOI: 10.1172/JCI19035Klarmann G.J., Hurt E.M., Mathews L.A. et al. Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis 2009;26(5):433–46. DOI: 10.1007/s10585-009-9242-2Atawia I.M., Kushwaha P.P., Verma S. et al. Inhibition of Wnt/β-catenin pathway overcomes therapeutic resistance to abiraterone in castration-resistant prostate cancer. Mol Carcinog 2023;62(9):1312–24. DOI: 10.1002/mc.23565Liu Y.M., Wu A.D., Chen Y. et al. Gastrodin inhibits prostate cancer proliferation by targeting canonical Wnt/β-catenin signaling pathway. Med Oncol 2023;41(1):32. DOI: 10.1007/s12032-023-02254-9Saito S., Ando K., Sakamoto S. et al. The LAT1 inhibitor JPH203 suppresses the growth of castration-resistant prostate cancer through a CD24-mediated mechanism. Cancer Sci 2024;115(7):2461–72. DOI: 10.1111/cas.16191Lee M.H., Kundu J.K., Keum Y.S. et al. Resveratrol Inhibits IL-6-induced transcriptional activity of AR and STAT3 in human prostate cancer LNCaP-FGC cells. Biomol Ther (Seoul) 2014;22(5):426–30. DOI: 10.4062/biomolther.2014.061Cao H., Feng Y., Sun P. et al. Zhoushi Qiling decoction inhibits proliferation of human prostate cancer cells through IL6/STAT3 pathway. J Cancer 2023;14(12):2246–54. DOI: 10.7150/jca.84943Cai F., Guo S., Huang S. et al. Rubimaillin suppresses proliferation, migration and invasion of prostate cancer cells via the Notch-1/MMP signaling pathway. Cell Mol Biol (Noisy-le-grand) 2020;66(2):130–4.Cai M., Ge S., Hong Y. et al. Tegaserod maleate exerts anti-tumor effects on prostate cancer via repressing sonic hedgehog signaling pathway. Mol Med 2025;31(1):30. DOI: 10.1186/s10020-025-01080-1